<DOC>
	<DOCNO>NCT00000726</DOCNO>
	<brief_summary>To explore safety usefulness foscarnet , antiviral agent , treatment cytomegalovirus ( CMV ) retinitis . Untreated CMV retinitis rapidly progressive , blind disease AIDS patient . The manner foscarnet break body effect increase periodic intravenous dos also study . Foscarnet active vitro ( test tube ) herpes virus , include CMV , inhibit virus DNA polymerases , enzymes necessary virus replication , without affect cellular DNA polymerase . Opportunistic CMV disease AIDS usually see retinitis , colitis , esophagitis , hepatitis , pancreatitis , encephalitis , pneumonia . Ganciclovir use treat AIDS patient CMV disease cause severe neutropenia ( low neutrophil cell count ) . Foscarnet suppress production neutrophil leukocytes ( myelosuppression ) show vitro activity HIV .</brief_summary>
	<brief_title>Foscarnet Treatment Serious CMV Retinitis Infection Patients With Acquired Immunodeficiency Syndrome</brief_title>
	<detailed_description>Foscarnet active vitro ( test tube ) herpes virus , include CMV , inhibit virus DNA polymerases , enzymes necessary virus replication , without affect cellular DNA polymerase . Opportunistic CMV disease AIDS usually see retinitis , colitis , esophagitis , hepatitis , pancreatitis , encephalitis , pneumonia . Ganciclovir use treat AIDS patient CMV disease cause severe neutropenia ( low neutrophil cell count ) . Foscarnet suppress production neutrophil leukocytes ( myelosuppression ) show vitro activity HIV . Treatment give total 10 week 2-week induction regimen follow randomization daily maintenance foscarnet 8 week . If induction therapy tolerate without unexpected toxicity , patient allow self-administer foscarnet home via central venous catheter may receive 11 day induction therapy self-administration outpatient basis . Foscarnet administer open-label fashion investigator patient know dose . Within study , 8 patient upon enter 2nd week maintenance foscarnet therapy treat zidovudine ( AZT ) .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Retinitis</mesh_term>
	<mesh_term>Cytomegalovirus Retinitis</mesh_term>
	<mesh_term>Foscarnet</mesh_term>
	<mesh_term>Phosphonoacetic Acid</mesh_term>
	<criteria>Exclusion Criteria Concurrent Medication : Excluded : Acyclovir . Zidovudine ( AZT ) . Any potentially nephrotoxic agent , especially aminoglycosides , pentamidine , amphotericin B . Prior Medication : Excluded : Ganciclovir . Foscarnet . Excluded within 7 day study entry : Any potentially nephrotoxic agent . Excluded within 14 day study entry : Cytomegalovirus hyperimmune globulin therapeutic dos . Immunomodulators . Biologic response modifier . Investigational agent . Amphotericin B maintenance systemic mycosis . Known allergy foscarnet . Active AIDSdefining opportunistic infection cytomegalovirus ( CMV ) include systemic mycosis , pulmonary neurologic impairment ( comatose ) . Patient must diagnose : AIDS CDC Group IV.C . Cytomegalovirus ( CMV ) retinitis identify characteristic ophthalmoscopic appearance verify fundus photography . One pending culture CMV blood urine prior study entry .</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Retinitis</keyword>
	<keyword>AIDS-Related Opportunistic Infections</keyword>
	<keyword>Foscarnet</keyword>
	<keyword>Cytomegalovirus Infections</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>Antiviral Agents</keyword>
</DOC>